Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 2/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.52 |
| ▸ | BACE1 | P56817 | 2/20 | 0.49 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.47 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3360393 | 1.00 | ACKR3 (0.53) | ACKR3SIGMAR1BACE1CAPN1CAPN2 | |
| SCHEMBL30750666 | 0.89 | SIGMAR1 (0.61) | ACKR3SIGMAR1MEN1MAPTKMT2A | |
| SCHEMBL6220780 | 0.89 | SIGMAR1 (0.61) | ACKR3SIGMAR1MEN1MAPTKMT2A | |
| SCHEMBL13496112 | 0.86 | P2RX7 (0.54) | ACKR3CTSKP2RX7 | |
| SCHEMBL13496161 | 0.85 | CAPN1 (0.55) | ACKR3CAPN1CAPN2CTSKMEN1 | |
| SCHEMBL18751224 | 0.85 | SIGMAR1 (0.59) | ACKR3SIGMAR1MEN1MAPTKMT2A | |
| SCHEMBL25374458 | 0.83 | SIGMAR1 (0.67) | ACKR3SIGMAR1 | |
| SCHEMBL29889007 | 0.82 | SIGMAR1 (0.56) | ACKR3SIGMAR1BACE1P2RX7MEN1 | |
| SCHEMBL21069668 | 0.80 | LMNA (0.58) | ACKR3SIGMAR1BACE1P2RX7MEN1 | |
| SCHEMBL828979 | 0.80 | SIGMAR1 (0.66) | ACKR3SIGMAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100036122-A1 | CLEAVAGE AGENT SELECTIVELY ACTING ON SOLUBLE ASSEMBLY OF AMYLOIDOGENIC PEPTIDE OR PROTEIN | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KP) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100036122-A1 | CLEAVAGE AGENT SELECTIVELY ACTING ON SOLUBLE ASSEMBLY OF AMYLOIDOGENIC PEPTIDE OR PROTEIN | APP, BACE1, IAPP | ACKR3 2018/4885SIGMAR1 4672/4885BACE1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.